Format

Send to

Choose Destination
Korean J Gastroenterol. 2018 Nov 25;72(5):237-244. doi: 10.4166/kjg.2018.72.5.237.

[New Helicobacter pylori Eradication Therapies].

[Article in Korean]

Author information

1
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

Abstract

While the prevalence of Helicobacter pylori (H. pylori) infection is decreasing in Korea, the incidence of gastric cancer remains high, emphasizing the importance of H. pylori eradication. A new treatment strategy is needed as the eradication rate with standard triple therapy, which is currently the standard first-line regimen for H. pylori infection, has decreased below the optimum level. The major cause of eradication failure is increased antibiotic resistance. Sequential, concurrent, and hybrid therapies that include clarithromycin produce higher eradication rates than conventional standard triple therapy. However, the effectiveness of these treatments is limited in regions where the resistance rate to various antibiotics is high. Bismuth quadruple therapy is another alternative therapy, but again the eradication rate is not sufficiently high. Tailored therapy based on individual characteristics, including antibiotic susceptibility, may be ideal, but there are several limitations for clinical application and further research is needed. New potassium-competitive acid blocker-based therapies could emerge as effective alternatives in the near future. A consensus is needed to establish a strategy for applying new eradication therapies in Korea.

KEYWORDS:

Guideline; Helicobacter pylori; Korea; Therapeutics

PMID:
30642139
DOI:
10.4166/kjg.2018.72.5.237
Free full text

Supplemental Content

Full text links

Icon for The Korean Society of Gastroenterology
Loading ...
Support Center